Tectonic Therapeutic Shares Rise in Premarket on Positive Data for XT45 Drug

Dow Jones

Oct 30

By Adriano Marchese

Tectonic Therapeutic shares jumped in premarket trading Thursday after the company reported positive trial data for its treatment of pulmonary hypertension and heart failure.

Shares traded 23% higher ahead of the opening bell at $22.90.

Data from the phase 1b part B acute hemodynamic clinical trial showed that a single intravenous dose of its TX45 drug was well tolerated and brought on meaningful improvements in both left heart function and pulmonary hemodynamics.

TX45 is Tectonic's new drug that aims to improve heart and lung function in patients with group 2 pulmonary hypertension and heart failure. This condition involves elevated blood pressure in the lungs due to left heart disease, leading to poor heart and lung performance.

Tectonic also noted that there were no serious health issues and the drug was well tolerated among the cohort of patients.

Write to Adriano Marchese at adriano.marchese@wsj.com

(END) Dow Jones Newswires

October 30, 2025 08:25 ET (12:25 GMT)

Copyright (c) 2025 Dow Jones & Company, Inc.

At the request of the copyright holder, you need to log in to view this content

LOGIN / SIGN UP

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

1
2
3
4
5
6
7
8
9
10

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/news/2579149718"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2579149718\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/2579149718?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-10-30 20:25","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2579149718","market":"nz","top_or_hot":-1,"title":"Tectonic Therapeutic Shares Rise in Premarket on Positive Data for XT45 Drug","media":"Dow Jones","content":"<font class=\"NormalMinus1\" face=\"Arial\">\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  By Adriano Marchese \n</p>\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  <a href=\"https://laohu8.com/S/TECX\">Tectonic Therapeutic</a> shares jumped in premarket trading Thursday after the company reported positive trial data for its treatment of pulmonary hypertension and heart failure. \n</p>\n<p>\n  Shares traded 23% higher ahead of the opening bell at $22.90. \n</p>\n<p>\n  Data from the phase 1b part B acute hemodynamic clinical trial showed that a single intravenous dose of its TX45 drug was well tolerated and brought on meaningful improvements in both left heart function and pulmonary hemodynamics. \n</p>\n<p>\n  TX45 is Tectonic's new drug that aims to improve heart and lung function in patients with group 2 pulmonary hypertension and heart failure. This condition involves elevated blood pressure in the lungs due to left heart disease, leading to poor heart and lung performance. \n</p>\n<p>\n  Tectonic also noted that there were no serious health issues and the drug was well tolerated among the cohort of patients. \n</p>\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  Write to Adriano Marchese at adriano.marchese@wsj.com \n</p>\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  (END) Dow Jones Newswires\n</p>\n<p>\n  October 30, 2025 08:25 ET (12:25 GMT)\n</p>\n<p>\n  Copyright (c) 2025 Dow Jones &amp; Company, Inc.\n</p>\n</font>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Tectonic Therapeutic Shares Rise in Premarket on Positive Data for XT45 Drug</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nTectonic Therapeutic Shares Rise in Premarket on Positive Data for XT45 Drug\n</h2>\n\n<h4 class=\"meta\">\n\n\n<div class=\"head\" \">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/150f88aa4d182df19190059f4a365e99);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Dow Jones </p>\n<p class=\"h-time\">2025-10-30 20:25</p>\n</div>\n\n</div>\n\n\n</h4>\n\n</header>\n<article>\n<font class=\"NormalMinus1\" face=\"Arial\">\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  By Adriano Marchese \n</p>\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  <a href=\"https://laohu8.com/S/TECX\">Tectonic Therapeutic</a> shares jumped in premarket trading Thursday after the company reported positive trial data for its treatment of pulmonary hypertension and heart failure. \n</p>\n<p>\n  Shares traded 23% higher ahead of the opening bell at $22.90. \n</p>\n<p>\n  Data from the phase 1b part B acute hemodynamic clinical trial showed that a single intravenous dose of its TX45 drug was well tolerated and brought on meaningful improvements in both left heart function and pulmonary hemodynamics. \n</p>\n<p>\n  TX45 is Tectonic's new drug that aims to improve heart and lung function in patients with group 2 pulmonary hypertension and heart failure. This condition involves elevated blood pressure in the lungs due to left heart disease, leading to poor heart and lung performance. \n</p>\n<p>\n  Tectonic also noted that there were no serious health issues and the drug was well tolerated among the cohort of patients. \n</p>\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  Write to Adriano Marchese at adriano.marchese@wsj.com \n</p>\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  (END) Dow Jones Newswires\n</p>\n<p>\n  October 30, 2025 08:25 ET (12:25 GMT)\n</p>\n<p>\n  Copyright (c) 2025 Dow Jones &amp; Company, Inc.\n</p>\n</font>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK4139","symbol_name":"生物科技","start_time":0,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","article_id":"2579149718","we_media_id":"106","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2579149718","pubTimestamp":1761827100,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Dow Jones","introduction":"Dow Jones publishes the world’s most trusted business news and financial information in a variety of media.","home_visible":0,"id":"106","head_image":"https://static.tigerbbs.com/150f88aa4d182df19190059f4a365e99"},"summary":"Tectonic Therapeutic shares jumped in premarket trading Thursday after the company reported positive trial data for its treatment of pulmonary hypertension and heart failure.Shares traded 23% higher ahead of the opening bell at $22.90.Data from the phase 1b part B acute hemodynamic clinical trial showed that a single intravenous dose of its TX45 drug was well tolerated and brought on meaningful improvements in both left heart function and pulmonary hemodynamics.TX45 is Tectonic's new drug that aims to improve heart and lung function in patients with group 2 pulmonary hypertension and heart failure. This condition involves elevated blood pressure in the lungs due to left heart disease, leading to poor heart and lung performance.Tectonic also noted that there were no serious health issues and the drug was well tolerated among the cohort of patients.","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"BK4139":"生物科技","TECX":"Tectonic Therapeutic, Inc."},"translate_title":"由于XT45药物的积极数据，Tectonic Therapeutic股价在盘前上涨","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"TECX":0.9},"content_text":"By Adriano Marchese \n\n\n \n\n\nTectonic Therapeutic shares jumped in premarket trading Thursday after the company reported positive trial data for its treatment of pulmonary hypertension and heart failure. \n\n\n  Shares traded 23% higher ahead of the opening bell at $22.90. \n\n\n  Data from the phase 1b part B acute hemodynamic clinical trial showed that a single intravenous dose of its TX45 drug was well tolerated and brought on meaningful improvements in both left heart function and pulmonary hemodynamics. \n\n\n  TX45 is Tectonic's new drug that aims to improve heart and lung function in patients with group 2 pulmonary hypertension and heart failure. This condition involves elevated blood pressure in the lungs due to left heart disease, leading to poor heart and lung performance. \n\n\n  Tectonic also noted that there were no serious health issues and the drug was well tolerated among the cohort of patients. \n\n\n \n\n\n  Write to Adriano Marchese at adriano.marchese@wsj.com \n\n\n \n\n\n  (END) Dow Jones Newswires\n\n\n  October 30, 2025 08:25 ET (12:25 GMT)\n\n\n  Copyright (c) 2025 Dow Jones & Company, Inc.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"dataReport","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":true,"code":"91000000","status":"200"}}}